Castle Biosciences financials
$34.88−2.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $103.5M | $83.7M | $87.0M | $83.0M | $86.2M | $88.0M | $86.3M | $85.8M | $87.0M | $73.0M | $66.1M | $61.5M |
| Gross profit | $79.8M | $63.1M | $68.7M | $64.3M | $68.6M | $71.6M | $70.1M | $70.2M | $72.5M | $59.1M | $53.7M | $50.2M |
| Gross margin | 77.1% | 75.5% | 79.0% | 77.5% | 79.5% | 81.4% | 81.3% | 81.8% | 83.3% | 81.0% | 81.2% | 81.6% |
| Operating income | -$3.1M | -$18.4M | -$3.8M | -$6.8M | -$4.3M | -$27.9M | $4.0M | $5.1M | $5.0M | -$5.5M | -$5.7M | -$9.6M |
| Net income | -$2.1M | -$14.5M | -$2.3M | -$501.0K | $4.5M | -$25.8M | $9.6M | $2.3M | $8.9M | -$2.5M | -$2.6M | -$6.9M |
| Net margin | −2.0% | −17.4% | −2.7% | −0.6% | 5.2% | −29.4% | 11.1% | 2.6% | 10.3% | −3.5% | −3.9% | −11.2% |
| Diluted EPS | $-0.07 | $-0.49 | $-0.08 | $-0.02 | $0.15 | $-0.90 | $0.31 | $0.08 | $0.31 | $-0.09 | $-0.10 | $-0.26 |
| EBITDA | $1.0M | -$14.5M | -$50.0K | -$3.0M | -$837.0K | $1.8M | $9.8M | $8.6M | $8.4M | -$2.1M | -$5.7M | -$6.5M |
| Operating cash flow | $15.2M | -$22.1M | $26.9M | $22.6M | $20.8M | -$6.0M | $24.4M | $23.3M | $24.0M | -$6.8M | $18.6M | $5.0M |
| Free cash flow | $6.6M | -$34.6M | $19.7M | $7.8M | $11.6M | -$10.8M | $16.8M | $17.0M | $18.8M | -$16.0M | $14.8M | $2.6M |
| Diluted shares | 30.4M | 29.9M | 28.7M | 29.1M | 29.5M | 28.6M | 31.4M | 29.4M | 28.7M | 27.5M | 27.0M | 26.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $62.1M | $63.8M | $116.7M | $85.6M | $82.2M | $89.7M |
| Short-term investments | $204.7M | $197.9M | $182.8M | $202.0M | $193.7M | $185.5M |
| Total debt | $10.3M | $10.4M | $10.4M | $10.4M | $10.4M | $10.4M |
| Total assets | $561.2M | $547.8M | $578.6M | $562.8M | $544.7M | $501.7M |
| Total liabilities | $91.1M | $86.4M | $107.7M | $95.7M | $89.4M | $61.4M |
| Shareholders' equity | $470.0M | $461.4M | $470.9M | $467.0M | $455.4M | $440.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology